Champions Oncology annual meeting results: all director nominees elected, auditor ratified, say-on-pay approved

On October 19, 2023, Champions Oncology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The following matters were submitted to a vote of the stockholders at the Annual Meeting and the voting results were as follows: 1. Election of Directors. The seven director nominees named in the Company's 2023 proxy statement were elected to serve for a one-year term expiring at the 2024 Annual Meeting of Stockholders or until their successors are duly elected and qualified, based upon the following votes: Director Nominee Votes For Votes Withheld Broker Non-Vote Ronnie Morris, M.D. 8,988,585 723,727 334,282 Joel Ackerman 8,556,358 1,155,954 334,282 David Sidransky, M.D. 8,126,259 1,586,053 334,282 Daniel Mendelson 8,313,289 1,399,023 334,282 Robert Brainin 8,454,904 1,257,408 334,282 Scott R. Tobin 9,654,012 58,300 334,282 Philip Breitfeld, M.D. 9,658,058 54,254 334,282

3. Non-binding Advisory Resolution Relating to the Compensation of the Company’s Named Executive Officers. The proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as described in the Company's 2023 proxy statement, was approved by the following votes: Votes For Votes Against Abstain Broker Non-Vote 9,444,385 10,040 257,887 334,282

2. Ratification of Appointment of Independent Registered Accounting Firm. The appointment of EisnerAmper LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024, was ratified as follows: Votes For Votes Against Abstain 10,041,893 4,303 398